Hematopoietic stem cell regeneration (HSC regeneration)

Hematopoietic stem cell (HSC) regeneration is the physiological and therapeutic process by which the bone marrow restores the production of all blood cell lineages following injury, chemotherapy, or transplantation (NIH, 2024). This process is governed by a complex interplay between intrinsic signaling pathways, such as Notch and Wnt, and extrinsic factors within the bone marrow niche, including cytokines like Stem Cell Factor (SCF) and Thrombopoietin (TPO) (NIH, 2022). In clinical practice, HSC regeneration is promoted using growth factors like G-CSF or TPO receptor agonists to accelerate recovery from neutropenia and thrombocytopenia (BasicMedicalKey, 2016). It is a cornerstone of regenerative medicine, particularly in treating bone marrow failure syndromes and hematologic malignancies (NIH, 2024). Emerging therapies also target niche-derived factors and small molecules like Prostaglandin E2 to enhance the homing and self-renewal of transplanted stem cells (J Clin Invest, 2022). Successful regeneration is often monitored using biomarkers such as CD34+ cell counts and the recovery of absolute neutrophil levels (Frontiers, 2022).

Other names

HSC regenerationHematopoietic reconstitutionHematopoietic recoveryBlood stem cell regenerationHSC self-renewal

Stimulation of hematopoietic stem and progenitor cells (HSPCs) through activation of cytokine receptors (e.g., G-CSFR, MPL), modulation of the bone marrow niche (e.g., CXCR4 antagonism), or enhancement of self-renewal pathways (e.g., Notch, Wnt, PGE2 signaling) to restore blood cell production.